ValueGene Inc.

ValueGene Inc. specializes in developing primer oligonucleotides for virus PCR and viral detection, providing essential tools for molecular diagnostics in healthcare and research sectors. Founded in 2005 and headquartered in San Diego, US, ValueGene Inc. focuses on providing specialized primer oligonucleotides.

In June 2016, the company was acquired by Integrated DNA Technologies, a subsidiary of Summit Partners. The founder's history is not detailed in the available information. ValueGene, Inc. specializes in the development and provision of primer oligonucleotides specifically designed for virus PCR (Polymerase Chain Reaction) and viral detection.

These primer oligonucleotides are essential tools in various molecular diagnostics applications, enabling precise and reliable identification of viral pathogens in clinical samples. The products offered by ValueGene aim to address critical needs in the healthcare and research sectors, particularly in the context of infectious disease control and surveillance. Their target clientele includes laboratories, hospitals, and research institutions engaged in virology and infectious disease diagnostics. ValueGene’s products are marketed primarily in North America, Europe, and parts of Asia, catering to a diverse customer base that relies on accurate viral detection methods for both clinical and research purposes.

The revenue model of ValueGene, Inc. is primarily structured around direct sales of its primer oligonucleotides to B2B clients, including research institutions and diagnostic laboratories. Transactions typically involve clients placing orders for bulk quantities of these specialized products, which are then fulfilled by the company. While specific pricing plans for individual products are not disclosed, the company’s offerings include options for one-time purchases as well as potential bulk pricing agreements for larger orders.

The business may also establish partnerships with distributors or wholesalers to expand its reach and enhance distribution capabilities. This transactional framework supports ongoing relationships with clients who depend on ValueGene's innovative solutions for their viral detection needs. Following its acquisition in June 2016 by Integrated DNA Technologies, ValueGene Inc. aims to leverage synergies for future growth.

The company is set to design and launch new primer oligonucleotides tailored for emerging viral pathogens, with potential release dates planned for late 2023. Additionally, ValueGene is targeting expansion into Asian markets, focusing specifically on regions like Southeast Asia and East Asia by mid-2024. Recent funding will be allocated to enhance R&D capabilities and support these new product developments, as well as strengthen market penetration in the identified geographic areas.